Your session is about to expire
← Back to Search
Radiation Therapy
Stereotactic Radiotherapy for Oligometastatic Prostate Cancer (CROP Trial)
Phase 1 & 2
Waitlist Available
Led By Patrick Cheung, M.D.
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cumulative incidence at 2 years
Awards & highlights
No Placebo-Only Group
Summary
This trial looks at whether using two cancer treatments together is safe and better than using just one of them for patients with a limited number of metastatic tumours.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ cumulative incidence at 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cumulative incidence at 2 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of late radiotherapy toxicities after stereotactic radiotherapy to all sites of disease
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Stereotactic radiotherapyExperimental Treatment1 Intervention
Stereotactic radiotherapy will be delivered to the prostate (if not previously treated) and to all metastatic tumours.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
stereotactic radiotherapy
2014
N/A
~60
Find a Location
Who is running the clinical trial?
Sunnybrook Health Sciences CentreLead Sponsor
681 Previous Clinical Trials
1,565,668 Total Patients Enrolled
32 Trials studying Prostate Cancer
11,685 Patients Enrolled for Prostate Cancer
Patrick Cheung, M.D.Principal InvestigatorToronto Sunnybrook Regional Cancer Centre